HOUSTON, April 9, 2019 /PRNewswire/ -- Soliton, Inc.,
(NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
it has completed the first evaluation timepoint for its proof of
concept clinical trial for the treatment of cellulite. Results for
a single acoustic shockwave treatment are being assessed by a
blinded group of clinicians.
The study, conducted by Dr. Michael
Kaminer at SkinCare Physicians in Boston, MA, in collaboration with Dr.
Elizabeth Tanzi of Capital Laser and
Skin Care, concluded evaluation of safety and efficacy for all
patients through the initial 12-week time point. The study is
designed to evaluate results at both the 12-week and 26-week
timepoints from initial treatment in order to assess both near-term
and long-term effects.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
"We are pleased with how quickly this trial has progressed,"
commented Dr. Chris Capelli,
Soliton's President and CEO. "We look forward to disclosing the
independent assessment of the data from this trial in the near
future. We believe the opportunity in the treatment of cellulite
could be very significant for Soliton."
Dr. Michael Kaminer of SkinCare
Physicians added: "Having led the clinical development of Cellfina,
the only treatment with FDA clearance for producing long-term
reduction of cellulite, I am particularly aware of the unmet need
in the treatment of cellulite. Having a non-invasive alternative
treatment could provide a real benefit for patients while also
expanding the breadth of services offered by clinicians."
Drs. Kaminer and Tanzi are members of Soliton's Scientific
Advisory Board.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to accelerate the removal of unwanted tattoos (RAP device).
In addition, higher energy versions of acoustic pulse devices are
in early stages of development for potential stand-alone treatment
of cellulite and other indications. Both products are
investigational and are not available for sale in the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton's
acoustic shockwave device to reduce cellulite in the proof of
concept clinical trial. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by
such forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT:
|
Joe Dorame, Joe
Diaz & Robert Blum
|
|
Lytham Partners,
LLC
|
|
602-889-9700
|
|
soly@lythampartners.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-completes-cellulite-clinical-trials-300827545.html
SOURCE Soliton, Inc.